BioSpace News Archive

Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for Dupixent® 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis, a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow.

Arrayjet, a leading provider of inkjet liquid-handling solutions, introduced Mercury, a new core range of five instruments for ultra-low-volume liquid dispensing.

Venatorx Pharmaceuticals, Inc. announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.

Spectrum Pharmaceuticals today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022.

Akili Interactive today announced that management will present at Chardan’s Prescription Digital Therapeutics Half-Day Summit on Monday, April 11, 2022 at 2:00 p.m. E.T.

Bruker Expands dia-PASEF ® on the timsTOF 4D Proteomics and Epiproteomics Platform to Identify up to 13,000 Protein Groups with 1% FDR.

Independent specialty pharmacy DirectRx announced today the launch and implementation of DirectFlow technology, designed to streamline the process of communicating patient information between physicians’ offices and the DirectRx pharmacy team.

Meridian Michigan announced today that it has appointed Dr. Kay Judge as its new Chief Medical Officer, effective April 10 , 2022.

Aspen Surgical Products announced today that Audax has closed on a single-asset continuation fund to support additional investment in Aspen, reaffirming its commitment to the company’s growth strategy.

Albany NY, United States: In the recent times, the global market for immunohistochemistry has observed a noticeable rise and is anticipated to experience an upswing in its valuation in the years to come.